Key terms
About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MRUS news
Mar 28
9:52am ET
Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls
Mar 28
7:00am ET
Merus initiated with a Buy at Truist
Mar 11
5:25pm ET
Merus management to meet with Jefferies
Mar 11
9:10am ET
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and MoonLake Immunotherapeutics (MLTX)
Mar 11
7:10am ET
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
Mar 11
4:55am ET
Merus management to meet with Jefferies
Mar 10
10:26pm ET
Merus management to meet with Jefferies
Mar 08
7:47am ET
Merus price target raised to $52 from $44 at BofA
Mar 08
5:21am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 08
2:05am ET
3 Best Stocks to Buy Now, 3/8/2024, According to Top Analysts
Mar 07
6:15am ET
Strategic Collaboration Boosts Merus’s Prospects: A Buy Rating with Increased Price Target
Mar 06
8:15am ET
Merus to potentially receive $56M in deal with Gilead to discover antigens
Mar 06
8:12am ET
Gilead receives option to license novel trispecific therapeutics in Merus deal
Mar 06
8:10am ET
Merus to receive $56M upfront in deal with Gilead to discover antigens
Mar 04
7:30am ET
Merus added to Conviction List at Needham
Mar 01
7:31am ET
Merus price target raised to $54 from $45 at Canaccord
Mar 01
12:58am ET
Merus’s Upgraded Outlook: Buy Rating and Price Target Boost Amid Promising Drug Trials and Financial Stability
Feb 29
9:43am ET
Merus price target raised to $65 from $40 at Stifel
Feb 29
8:17am ET
Stifel Nicolaus Keeps Their Buy Rating on Merus (MRUS)
Feb 29
7:28am ET
Buy Rating Affirmed on Merus’s Stock Amid Strong Clinical Developments and Market Potential
Feb 29
6:14am ET
Merus price target raised to $65 from $48 at H.C. Wainwright
Feb 28
7:15pm ET
TD Cowen Keeps Their Buy Rating on Merus (MRUS)
Feb 28
5:05pm ET
Merus files automatic mixed securities shelf
Feb 28
4:36pm ET
Merus reports 2023 EPS ($3.00), consensus ($2.68)
Feb 15
9:18am ET
Merus price target raised to $56 from $48 at Guggenheim
Feb 08
9:11am ET
Merus price target raised to $44 from $38 at BofA
Feb 08
6:55am ET
Buy Rating on Merus Stock Amid Anticipated Phase 3 Trial and Promising Treatment Efficacy for HNSCC
No recent press releases are available for MRUS
MRUS Financials
Key terms
Ad Feedback
MRUS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MRUS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
